Dyskinesia Drugs In Development Pipeline Report 2021 – ResearchAndMarkets.com

Dyskinesia Drugs In Development Pipeline Report 2021 – ResearchAndMarkets.com




Dyskinesia Drugs In Development Pipeline Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dyskinesia (Central Nervous System) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Dyskinesia – Drugs In Development, 2021, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

Dyskinesia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 15, 8, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

The Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Key Topics Covered:

  • Introduction
  • Dyskinesia – Overview
  • Dyskinesia – Therapeutics Development
  • Dyskinesia – Companies Involved in Therapeutics Development
  • Dyskinesia – Drug Profiles
  • Dyskinesia – Dormant Projects
  • Dyskinesia – Discontinued Products
  • Dyskinesia – Product Development Milestones
  • Appendix

Companies Mentioned

  • Addex Therapeutics Ltd
  • AEON Biopharma Inc
  • AfaSci Inc
  • Amarantus Bioscience Holdings Inc
  • Astraea Therapeutics LLC
  • Bod Australia Ltd
  • Cannabis Science Inc
  • Celon Pharma SA
  • Cerevance Inc
  • Cerevel Therapeutics Holdings Inc
  • Contera Pharma ApS
  • Daewoong Pharmaceutical Co Ltd
  • DanPET AB
  • Domain Therapeutics SA
  • EpiVax Inc
  • GraySpace Therapeutics Inc
  • Hua Medicine Shanghai Ltd
  • Ipsen SA
  • IRLAB Therapeutics AB
  • Jazz Pharmaceuticals Plc
  • Junaxo Inc
  • MapLight therapeutics Inc
  • Medytox Inc
  • Melior Pharmaceuticals II LLC
  • Merz Pharma GmbH & Co KgaA
  • MitoDys Therapeutics Ltd
  • Molomics Biotech SL
  • Motac Neuroscience Ltd
  • Neurim Pharmaceuticals Ltd
  • Neurocea Pharmaceuticals
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Newron Pharmaceuticals SpA
  • Nissan Chemical Corp
  • Novartis AG
  • OB Pharmaceuticals
  • Peptron Inc
  • PharmaTher Holdings Ltd
  • PolyCore Therapeutics LLC
  • Praxis Precision Medicines Inc
  • Revance Therapeutics Inc
  • Sage Therapeutics Inc
  • SalubRx Therapeutics Inc
  • Shionogi & Co Ltd
  • Sinopia Biosciences Inc
  • SOM Biotech SL
  • Sumitomo Dainippon Pharma Co Ltd
  • Tempero Bio
  • Teva Pharmaceutical Industries Ltd
  • Trevi Therapeutics Inc
  • Ultragenyx Pharmaceutical Inc
  • VistaGen Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/oeyx23

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900